Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 23,370 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 2nd, Michael Kaseta sold 1,091 shares of Liquidia stock. The shares were sold at an average price of $11.51, for a total transaction of $12,557.41.

Liquidia Price Performance

Shares of LQDA stock opened at $11.36 on Wednesday. The stock has a market capitalization of $961.48 million, a PE ratio of -6.97 and a beta of 0.23. The business’s 50 day simple moving average is $11.20 and its 200 day simple moving average is $11.01. Liquidia Co. has a one year low of $8.26 and a one year high of $16.99.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently modified their holdings of the company. Quest Partners LLC bought a new position in Liquidia during the second quarter worth $27,000. Clear Harbor Asset Management LLC bought a new stake in Liquidia during the third quarter valued at $100,000. Signaturefd LLC grew its holdings in Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares during the period. Ballentine Partners LLC bought a new position in shares of Liquidia in the 3rd quarter worth about $110,000. Finally, Whitcomb & Hess Inc. lifted its stake in shares of Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after purchasing an additional 1,074 shares during the period. 64.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of research reports. Scotiabank assumed coverage on Liquidia in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, January 9th. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, November 14th. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Liquidia has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).